SM
LAB icon

Sabby Management’s Standard BioTools LAB Stock Holding History

Sabby Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,312
Closed -$3.58M – 326
2015
Q4 		$3.58M Sell
3,312
-305
-8% -$3K 0.2% 80
2015
Q3 		$488K Buy
3,617
+3,172
+713% +$49.9K 0.02% 292
2015
Q2 		$1.08M Buy
+445
New +$14K 0.04% 217

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EA
Emerald Acquisition Seattle, Washington $51.8B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Sabby Management's LAB Position: Q2 2016 in Review

Sabby Management sold out of Standard BioTools (LAB) in Q2 2016, closing a stake of 139,506 shares — an estimated $1.13M sold.

Sabby Management first reported a position in LAB in Q2 2015 and held it in 4 quarters. The position peaked at $5.09M in Q3 2015. 97 funds tracked by Wall St. Rank hold LAB as of Q2 2016.

  • Sabby Management reported no remaining Standard BioTools position as of Q2 2016 after selling out during the quarter.
  • Sabby Management sold 139,506 Standard BioTools shares in Q2 2016, an estimated $1.13M.
  • Sabby Management first reported a position in Standard BioTools in Q2 2015 and held it in 4 quarters.
  • Sabby Management's Standard BioTools position peaked at $5.09M in Q3 2015.
  • 97 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.